Wang Yabo, Gonzalez Michel, Cheng Cai, Haouala Amina, Krueger Thorsten, Peters Solange, Decosterd Laurent-Arthur, van den Bergh Hubert, Perentes Jean Y, Ris Hans-Beat, Letovanec Igor, Debefve Elodie
Division of Thoracic and Vascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Lasers Surg Med. 2012 Apr;44(4):318-24. doi: 10.1002/lsm.22013. Epub 2012 Feb 23.
Visudyne®-mediated photodynamic therapy (PDT) at low drug/light conditions has shown to selectively enhance the uptake of liposomal doxorubicin in subpleural localized sarcoma tumors grown on rodent lungs without causing morphological alterations of the lung. The present experiments explore the impact of low-dose PDT on liposomal doxorubicin (Liporubicin™) uptake to different tumor types grown on rodent lungs.
Three groups of Fischer rats underwent subpleural generation of sarcoma, mesothelioma, or adenocarcinoma tumors on the left lung. At least five animals of each group (sarcoma, n = 5; mesothelioma, n = 7; adenocarcinoma, n = 5) underwent intraoperative low-dose (10 J/cm(2) at 35 mW/cm(2) ) PDT with 0.0625 mg/kg Visudyne® of the tumor and the lower lobe. This was followed by intravenous (IV) administration of 400 µg Liporubicin™. After a circulation time of 60 min, the tumor-bearing lung was processed for HPLC analyses. At least five animals per group underwent the same procedure but without PDT (sarcoma, n = 5; mesothelioma, n = 5; adenocarcinoma, n = 6). Five untreated animals per group underwent CD31 immunostaining of their tumors with histomorphometrical assessment of the tumor vascularization.
Low-dose PDT significantly enhanced Liporubicin™ uptake to all tumor types (sarcoma, P = 0.0007; mesothelioma, P = 0.001; adenocarcinoma, P = 0.02) but not to normal lung tissue compared to IV drug administration alone. PDT led to a significantly increased ratio of tumor to lung tissue drug uptake for all three tumor types (P < 0.05). However, the tumor drug uptake varied between tumor types and paralleled tumor vascular density. The vascular density was significantly higher in sarcoma than in adenocarcinoma (P < 0.001) and mesothelioma (P < 0.001), whereas there was no significant difference between adenocarcinoma and mesothelioma.
Low-dose Visudyne®-mediated PDT selectively enhances the uptake of systemically administered liposomal doxorubicin in tumors without affecting the drug uptake to normal lung. However, drug uptake varied significantly between tumor types and paralleled tumor vascular density.
在低药物/光照条件下,维速达尔介导的光动力疗法(PDT)已显示可选择性增强在啮齿动物肺部生长的胸膜下局部肉瘤肿瘤中脂质体阿霉素的摄取,且不会引起肺部形态改变。本实验探讨低剂量PDT对在啮齿动物肺部生长的不同肿瘤类型中脂质体阿霉素(里葆多™)摄取的影响。
三组Fischer大鼠在左肺进行胸膜下肉瘤、间皮瘤或腺癌肿瘤生成。每组至少五只动物(肉瘤,n = 5;间皮瘤,n = 7;腺癌,n = 5)接受术中低剂量(35 mW/cm²下10 J/cm²)PDT,肿瘤及下叶给予0.0625 mg/kg维速达尔。随后静脉注射400 μg里葆多™。循环60分钟后,对荷瘤肺进行高效液相色谱分析。每组至少五只动物接受相同操作但不进行PDT(肉瘤,n = 5;间皮瘤,n = 5;腺癌,n = 6)。每组五只未治疗动物对其肿瘤进行CD31免疫染色,并对肿瘤血管生成进行组织形态计量评估。
与单独静脉给药相比,低剂量PDT显著增强了所有肿瘤类型中里葆多™的摄取(肉瘤,P = 0.0007;间皮瘤,P = 0.001;腺癌,P = 0.02),但对正常肺组织无此作用。PDT导致所有三种肿瘤类型的肿瘤与肺组织药物摄取比显著增加(P < 0.05)。然而,肿瘤药物摄取因肿瘤类型而异,并与肿瘤血管密度平行。肉瘤中的血管密度显著高于腺癌(P < 0.001)和间皮瘤(P < 0.001),而腺癌和间皮瘤之间无显著差异。
低剂量维速达尔介导的PDT可选择性增强全身给药的脂质体阿霉素在肿瘤中的摄取,而不影响其对正常肺的药物摄取。然而,药物摄取在肿瘤类型之间差异显著,并与肿瘤血管密度平行。